Compare GSK plc (GSK) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs CarMax, Inc — how do they compare? GSK plc trades at $52.76 (market cap $101.34B), while CarMax, Inc trades at $58.56 (market cap $8.36B). The key difference: GSK plc is far larger — about 12.1× CarMax, Inc's market cap, and GSK plc pays a 3.49% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals.
| GSK | KMX | |
|---|---|---|
Market Cap | $101.34B | $8.36B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $63.53 |
52-Week Low | $36.20 | $30.88 |
Enterprise Value | $121.95B | $26.87B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
CarMax (KMX) stock trades at $59.87, up 7.43% in the last session, with a bullish technical signal from moving averages. The company reported Q1 2026 earnings that beat expectations, with revenue of $26.35 billion and net income of $500.56 million in 2025. However, net income margin remains thin at 0.84%, and the stock trades at a P/E of 36.61, which is elevated relative to historical norms. Recent news highlights a four-pillar strategic turnaround under new CEO Keith Barr, though an ongoing legal investigation adds uncertainty.
The outlook for KMX hinges on successful execution of its growth strategy amid a challenging used car market. Upside potential exists if cost controls and digital initiatives improve profitability, but risks include high debt levels, margin pressure, and the pending legal probe. Analyst consensus is mixed, with a Hold rating predominant and a price target of $48.91 below the current price, suggesting caution despite recent positive momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
